The NHS says it's facing its "worst-case scenario" after the number of people in hospital with flu jumped by 55% in a week in England. NHS England chief executive Sir Jim Mackey says between 5,000 and ...

A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Up is suddenly down in the world of aviation. And no, we’re not talking about pilot controls or making a cryptic Stranger Things reference. On Tuesday, Boeing’s CFO said the company has finally ...

The housing market keeps getting worse. Home prices have risen more than 50 percent since the start of the pandemic. About a third of Americans households now spend more than 30 percent of their ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

"Walk My Walk" by Breaking Rust is No. 1 on the 'Billboard' Country Digital Song Sales chart Jack Irvin has over five years of experience working in digital journalism, and he’s worked at PEOPLE since ...

Open enrollment for 2026 coverage on the Affordable Care Act exchanges is underway. And millions of consumers are now seeing just how expensive their health insurance policies will be without the ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...